SEC Form 4 · accession 0001462808-26-000007

Revolution Medicines, Inc. · RVMD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Stephen Michael Kelsey

Officer — See Remarks

Period of report

Sep 11, 2026

Accepted (ET)

Sep 15, 2026 · 6:00 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001628171

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 11, 2026	M	52,500	$42.45	A	344,376	D
Common Stock	Sep 11, 2026	M	40,031	$40.74	A	384,407	D
Common Stock^F2	Sep 11, 2026	S	800	$198.5502	D	383,607	D
Common Stock^F3	Sep 11, 2026	S	11,833	$200.1145	D	371,774	D
Common Stock^F4	Sep 11, 2026	S	13,368	$200.7769	D	358,406	D
Common Stock^F5	Sep 11, 2026	S	21,447	$201.7507	D	336,959	D
Common Stock^F6	Sep 11, 2026	S	18,869	$203.0606	D	318,090	D
Common Stock^F7	Sep 11, 2026	S	17,949	$203.8726	D	300,141	D
Common Stock^F8	Sep 11, 2026	S	4,995	$204.8427	D	295,146	D
Common Stock^F9,F10	Sep 11, 2026	S	3,270	$205.8075	D	291,876	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F11	$42.45	Sep 11, 2026	M	52,500	D	—	Mar 4, 2031	Common Stock	52,500	0	D
Stock Option (Right to Buy)^F12	$40.74	Sep 11, 2026	M	40,031	D	—	Mar 1, 2035	Common Stock	128,100	88,069	D

Explanation of responses

F1Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026.
F10Includes 76,251 restricted stock units.
F11Fully vested.
F12One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F2The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks

Senior Advisor to the Chief Executive Officer